Alnylam Pharmaceuticals
biopharmaceutical company
ALNY Nasdaq
ISIN US02043Q1076 SEC CIK 1178670 LEI 529900S3ZI14OWRJII50
Follow Alnylam Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$1.5B
+16.7% vs same quarter last year
Net income
$2.2B
+640.5% vs same quarter last year
EPS, diluted
$15.72
+634.6% vs same quarter last year
Operating cash flow
$341M
+14.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.7B | $313.7M |
| FY24 | $2.2B | −$278.2M |
| FY23 | $1.8B | −$440.2M |
| FY22 | $1B | −$1.1B |
| FY21 | $844.3M | −$852.8M |
| FY20 | $492.9M | −$858.3M |
| FY19 | $219.8M | −$886.1M |
| FY18 | $74.9M | −$761.5M |
| FY17 | $89.9M | −$490.9M |
| FY16 | $47.2M | −$410.1M |
| FY15 | - | −$290.1M |
| FY14 | - | −$360.4M |
| FY13 | - | −$89.2M |
| FY12 | - | −$106M |
| FY11 | - | −$57.6M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 81.8% | 13.5% | 8.4% |
| FY24 | 86.4% | −7.9% | −12.4% |
| FY23 | 85.3% | −15.4% | −24.1% |
| FY22 | 86.5% | −75.7% | −109% |
| FY21 | 86.4% | −83.9% | −101% |
| FY20 | 84.9% | −168.1% | −174.1% |
| FY19 | 88.6% | −427.5% | −403.2% |
| FY18 | 97.6% | −1087.6% | −1016.6% |
| FY17 | 100% | −556.2% | −545.9% |
| FY16 | - | −900.3% | −869.6% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $465.4M |
| FY24 | −$42.6M |
| FY23 | $41.9M |
| FY22 | −$613.3M |
| FY21 | −$718.1M |
| FY20 | −$685.3M |
| FY19 | −$418.6M |
| FY18 | −$689.5M |
| FY17 | −$487M |
| FY16 | −$372.3M |
| FY15 | −$202.1M |
| FY14 | −$174.6M |
| FY13 | −$72.7M |
| FY12 | −$124M |
| FY11 | −$88.4M |
- Alnylam Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Alnylam Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 8.4% | −30.6% |
| FY24 | −12.4% | −47% |
| FY23 | −24.1% | −58% |
| FY22 | −109% | −80.4% |
| FY21 | −101% | −71.9% |
| FY20 | −174.1% | −62.2% |
| FY19 | −403.2% | −46.3% |
| FY18 | −1016.6% | −49.6% |
| FY17 | −545.9% | −45.9% |
| FY16 | −869.6% | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |